Nectar Lifesciences Ltd. has announced a further extension to the completion date of its planned sale to Ceph Lifesciences Private Limited. The company has set a new target date of November 19, 2025, marking the third postponement of this significant corporate action.

Timeline of Extensions

The company has provided the following timeline for the completion of the sale:

Details of the Transaction

The transaction involves a slump sale of Nectar Lifesciences' business of manufacture, distribution, marketing, and sale of active pharmaceutical ingredients and formulations to Ceph Lifesciences Private Limited.

Regulatory Compliance

Nectar Lifesciences has made this announcement in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (LODR Regulations).

Shareholder Approval

The company had previously sought and received shareholder approval for this transaction. An Extraordinary General Meeting (EGM) was held on August 4, 2025, following notices dated July 7, 2025, and an addendum dated July 23, 2025.

Impact and Outlook

While the repeated extensions might raise questions about the progress of the deal, both Nectar Lifesciences and Ceph Lifesciences Private Limited have mutually agreed to this latest extension. The company has not provided specific reasons for the delay in its regulatory filing.

Investors and stakeholders will likely be watching closely for any further updates on this transaction, as it represents a significant change in Nectar Lifesciences' business structure. The completion of this sale could have substantial implications for the company's future operations and financial position.

Stakeholders are advised to refer to official company communications and regulatory filings for the most accurate and up-to-date information regarding this corporate action.

Nectar Lifesciences , a prominent player in the pharmaceutical industry, has recently made headlines with two significant developments that could impact its future operations and investor outlook.

Extension of Pharmaceutical Business Sale

Nectar Lifesciences has announced an extension to the expected completion date for the slump sale of its pharmaceutical business to Ceph Lifesciences Private Limited. The new target date for finalizing the transaction is set for October 20, 2025, as mutually agreed upon by both parties.

The slump sale encompasses a substantial portion of Nectar Lifesciences' operations, including the manufacture, distribution, marketing, and sale of active pharmaceutical ingredients and formulations. This strategic move, initially disclosed in July 2025, has been a topic of interest for stakeholders, with an Extraordinary General Meeting (EGM) held in August 2025 to discuss the matter.

Regulatory Scrutiny: DRI Search Operations

In a separate development, Nectar Lifesciences revealed that the Directorate of Revenue Intelligence (DRI), under the Central Board of Indirect Taxes & Customs, Ministry of Finance, Government of India, conducted search operations at various company premises. The search, which took place on September 15, 2025, was carried out under the provisions of the Customs Act, 1962.

Key points regarding the DRI search include:

• The company has fully cooperated with DRI officials during the proceedings.
• Nectar Lifesciences has responded to clarifications and details sought by the authorities.
• The company has committed to providing any further information required by the DRI.
• At this initial stage, the specific violations or contraventions alleged are not ascertainable.
• The financial impact of the search operations is currently undetermined.
• Despite the regulatory action, the company's operations and activities have continued without disruption.

Implications for Investors

These recent events present a mixed picture for Nectar Lifesciences and its stakeholders:

1. The extension of the slump sale completion date may indicate complexities in the transaction or potential adjustments to the deal structure. Investors will be keenly watching for any updates on this significant business restructuring.

2. The DRI search adds an element of regulatory uncertainty. While the company maintains that its operations remain unaffected, the outcome of this scrutiny could have implications for Nectar Lifesciences' compliance status and potentially its financial position.

As these situations unfold, shareholders and market watchers will be closely monitoring further disclosures from Nectar Lifesciences for any material impacts on the company's performance and strategic direction.

Nectar Lifesciences continues to navigate these challenges while maintaining its position in the pharmaceutical sector. The company's ability to successfully complete the slump sale and address any concerns arising from the DRI search will be crucial in shaping its future trajectory.